HomeInsightsStock Comparison

Laurus Labs Ltd vs Natco Pharma Ltd Stock Comparison

Laurus Labs Ltd vs Natco Pharma Ltd Stock Comparison

Last Updated on: Jun 23, 2025

Key Highlights

  • The Latest Trading Price of Laurus Labs Ltd is ₹ 655 as of 23 Jun 10:13.
  • The P/E Ratio of Laurus Labs Ltd changed from 13.5 on March 2020 to 92.4 on March 2025 . This represents a CAGR of 37.79% over 6 yearsThe P/E Ratio of Natco Pharma Ltd changed from 20 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The Market Cap of Laurus Labs Ltd changed from ₹ 3449 crore on March 2020 to ₹ 33099 crore on March 2025 . This represents a CAGR of 45.78% over 6 yearsThe Market Cap of Natco Pharma Ltd changed from ₹ 9215 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The revenue of Laurus Labs Ltd for the Mar '25 is ₹ 1778 crore as compare to the Dec '24 revenue of ₹ 1424 crore. This represent the growth of 24.88% The revenue of Natco Pharma Ltd for the Mar '25 is ₹ 1287 crore as compare to the Dec '24 revenue of ₹ 651.1 crore. This represent the growth of 97.71%.
  • The ebitda of Laurus Labs Ltd for the Mar '25 is ₹ 479.17 crore as compare to the Dec '24 ebitda of ₹ 294.57 crore. This represent the growth of 62.67% The ebitda of Natco Pharma Ltd for the Mar '25 is ₹ 614.4 crore as compare to the Dec '24 ebitda of ₹ 215.1 crore. This represent the growth of 185.63%.
  • The net profit of Laurus Labs Ltd changed from ₹ 28.4 crore to ₹ 233.87 crore over 8 quarters. This represents a CAGR of 186.96% The net profit of Natco Pharma Ltd changed from ₹ 420.3 crore to ₹ 406 crore over 8 quarters. This represents a CAGR of -1.72% .
  • The Dividend Payout of Laurus Labs Ltd changed from 10.13 % on March 2020 to 17.01 % on March 2025 . This represents a CAGR of 9.02% over 6 yearsThe Dividend Payout of Natco Pharma Ltd changed from 25.89 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Laurus Labs Ltd

  • Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology.
  • The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others.
  • The company currently operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh.
  • Three of these facilities manufacture APIs and ingredients, while the fourth facility produces Finished Dosage Formulations (FDFs) and one API. The company's strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing 'donor-funded access-to-medicines markets' of Sub-Saharan Africa, South-East Asia and Latin America.

About Natco Pharma Ltd

  • Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs).
  • The Company's focus is primarily on niche therapeutic areas and complex products.
  • It sells products in over 40 countries.
  • FDF products are sold in the United States, India, Europe and the rest of the world (RoW).
  • Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. Natco Pharma is also engaged in contract manufacturing business, whereby the company undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.

Laurus Labs Ltd News Hub

News

Laurus Labs to hold AGM

Laurus Labs announced that the 20th Annual General Meeting(AGM) of the company will be hel...

Read more

17 May 2025 09:22

News

Board of Laurus Labs recommends 2nd interim dividend

Laurus Labs announced that the Board of Directors of the Company at its meeting held on 24...

Read more

24 Apr 2025 16:52

News

Laurus Lab Q4 PAT soars to Rs 234 cr

Revenue from operations jumped 19.49% YoY to Rs 1,720.30 crore in Q4 FY25. Profit before t...

Read more

24 Apr 2025 17:20

News

Laurus Labs declare Quarterly Result

Laurus Labs will hold a meeting of the Board of Directors of the Company on 24 April 2025....

Read more

11 Apr 2025 09:55

News

Laurus Labs to acquire 26% stakes in Kurnool Renewables for Rs 35 cr

The strategic move will enable Laurus Labs to access 25.53 MW of renewable wind and solar ...

Read more

28 Mar 2025 15:15

News

Board of Laurus Labs approves investment of Rs 83.30 cr in KRKA Pharma

The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of a...

Read more

06 Mar 2025 19:44

Natco Pharma Ltd News Hub

News

Natco Pharma receives seven observations from USFDA Following Inspection at Kothur Facility

In a regulatory filing, the company stated that the USFDA conducted the inspection from 9 ...

Read more

20 Jun 2025 09:54

News

NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit

On conclusion of the inspection, the company received one observation in the Form-483. The...

Read more

14 Jun 2025 13:45

News

Natco Pharma's Mekaguda API unit completes USFDA inspection

NATCO Pharma announced conclusion of US FDA Inspection at its Mekaguda, Hyderabad Active P...

Read more

13 Jun 2025 16:27

News

Natco Pharma Ltd gains for third consecutive session

Natco Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 908...

Read more

11 Jun 2025 13:05

News

Natco Pharma gains after Q4 PAT rises 5% YoY to Rs 407 cr

Profit before tax (PBT) increased 5.9% YoY to Rs 505.90 crore in the quarter ended 31st Ma...

Read more

29 May 2025 15:50

News

Natco Pharma to conduct board meeting

Natco Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2025. ...

Read more

13 May 2025 10:19

SWOT Analysis Of Laurus Labs Ltd

Strength

6

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Natco Pharma Ltd

Strength

4

S

Weakness

3

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Laurus Labs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Natco Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Laurus Labs Ltd and Natco Pharma Ltd

Which company has a larger market capitalization, Laurus Labs Ltd or Natco Pharma Ltd?

Market cap of Laurus Labs Ltd is 35,116 Cr while Market cap of Natco Pharma Ltd is 15,677 Cr

What are the key factors driving the stock performance of Laurus Labs Ltd and Natco Pharma Ltd?

The stock performance of Laurus Labs Ltd and Natco Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Laurus Labs Ltd and Natco Pharma Ltd?

As of June 23, 2025, the Laurus Labs Ltd stock price is INR ₹651.2. On the other hand, Natco Pharma Ltd stock price is INR ₹875.3.

How do dividend payouts of Laurus Labs Ltd and Natco Pharma Ltd compare?

To compare the dividend payouts of Laurus Labs Ltd and Natco Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions